Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis.

Conclusions: Subclinical MPO-ANCA levels could distinguish future PLN from SLE without LN. MPO-ANCA manifests prior to clinical disease and subclinical dsDNAab to suggest that it may contribute directly to PLN pathogenicity. PMID: 29435367 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/29435367?dopt=Abstract

Source: Autoimmune Diseases - February 14, 2018 Category: Allergy & Immunology Tags: Autoimmune Dis Source Type: research